|
Dr. William Hunter is one of Angiotech's co-founders and currently serves as a member of its scientific and management teams. He has led Angiotech through significant corporate milestones from its initial rounds of private and public financings to product commercialization and profitability positioning the company as a world leader in the field of drug-device combination products. The company's lead product the TAXUSr drug-eluting coronary stent which was developed in collaboration with and now sold by Boston Scientific Corporation is implanted in over 1 million patients annually with sales in excess of US$2 billion.
Active in a variety of business and scientific organizations Dr. Hunter serves as a director for NeuroMed Technologies Inc. AnorMED Inc. and The Michael Smith Foundation for Health Research. He is also an advisory board member for the Biotechnology MBA Program at the University of Western Ontario's Ivey School of Business and an active member of the Government of British Columbia Premier's Technology Council. Dr. Hunter has been honored with many awards including most recently the 2005 BC Innovation Council's Cecil Green Award for Science and Technology Entrepreneurship and the 2005 Canadian Venture Capital Association's Entrepreneur of the Year.
Dr. Hunter received his BSc from McGill University and MSc and MD from the University of British Columbia. | 